Objective: Rate of lactate change is associated with in-hospital mortality in post-cardiac arrest patients. This association has not been validated in a prospective multicenter study. The objective of the current study was to determine the association between percent lactate change and outcomes in post-cardiac arrest patients. Design: Four-center prospective observational study conducted from June 2011 to March 2012. Setting: The National Post-Arrest Research Consortium is a clinical research network conducting research in post-cardiac arrest care. The network consists of four urban tertiary care teaching hospitals. Patients: Inclusion criteria consisted of adult out-of-hospital nontraumatic cardiac arrest patients who were comatose after return of spontaneous circulation. Interventions: None. Measurements and Main Results: The primary outcome was survival to hospital discharge, and secondary outcome was good neurologic outcome. We compared the absolute lactate levels and the differences in the percent lactate change over 24 hours between survivors and nonsurvivors and between subjects with good and bad neurologic outcomes. One hundred patients were analyzed. The median age was 63 years (interquartile range, 50-75) and 40% were female. Ninety-seven percent received thera-
peutic hypothermia, and overall survival was 46%. Survivors and patients with good neurologic outcome had lower lactate levels at 0, 12, and 24 hours (p < 0.01). In adjusted models, percent lactate decrease at 12 hours was greater in survivors (odds ratio, 2.2; 95% CI, 1.1-6.2) and in those with good neurologic outcome (odds ratio, 2.2; 95% CI, 1. 1-4.4) . Conclusion: Lower lactate levels at 0, 12, and 24 hours and greater percent decrease in lactate over the first 12 hours post cardiac arrest are associated with survival and good neurologic outcome. (Crit Care Med 2014; 42:1804-1811) Key Words: cardiac arrest; ischemia-reperfusion; lactate; lactic acidosis; perfusion; shock O ut-of-hospital cardiac arrest (OHCA) occurs in approximately 300,000 patients per year in the United States resulting in over 270,000 deaths and substantial neurologic morbidity in survivors (1) . Guidelines from the American Heart Association (AHA) and the European Resuscitation Council emphasize the importance of optimizing intra-arrest treatment, and recent guidelines also emphasize management of patients during the postarrest period (2, 3) .
The post-cardiac arrest period includes systemic illness from ischemia-reperfusion injury combined with the pathophysiologic derangements caused by the underlying etiology of the arrest. Management of the postarrest patient includes optimizing ventilation and oxygenation, optimizing tissue and organ perfusion, considering induced hypothermia when appropriate to promote neurologic recovery, and treating the underlying etiology of arrest (4) . Decrease in lactate is a surrogate marker for adequate tissue perfusion after return of spontaneous circulation (ROSC) and potentially serves as an endpoint for resuscitation. Current guidelines recommend measuring serial lactate levels in postarrest patients to ensure adequate perfusion; however, the International Liaison Committee on Resuscitation consensus statement recognizes a knowledge gap in this area since these recommendations are based, in part, from extrapolation from other diseases such as sepsis (4) (5) (6) . Two single-center, retrospective studies have addressed the association between lactate clearance and mortality and found that effective clearance was associated with decreased mortality (7, 8) .
We hypothesize that greater lactate reduction is associated with decreased mortality and good neurologic outcome. To test this hypothesis, we performed a preplanned analysis of a prospective, multicenter observational study of mitochondrial injury in postarrest patients. We examined the association between early lactate change and mortality and neurologic morbidity in postarrest patients. Second, we evaluated the difference in initial and subsequent lactate levels between survivors and nonsurvivors and between patients with good and poor neurologic outcome.
METHODS

Design and Setting
The National Post-Arrest Research Consortium (NPARC) is a clinical research network conducting research in post-cardiac arrest care. The network consists of four urban tertiary care teaching hospitals: Beth Israel Deaconess Medical Center (Boston, MA), University of Pennsylvania (Philadelphia, PA), University of Pittsburgh (Pittsburgh, PA), and Virginia Commonwealth University (Richmond, VA), and it was established to evaluate treatment strategies for people who are successfully resuscitated from OHCA. Patient care protocols for these hospitals have been reported previously (9) . The NPARC network was funded initially to characterize mitochondrial injury in the postarrest period. The current investigation is a preplanned analysis of data collected in the initial prospective observational cohort study.
Study Population
The study population of interest consisted of OHCA patients who presented to the emergency department (ED) at one of the four NPARC centers during the period from June 2011 to March 2012. Inclusion criteria consisted of adult patients 18 years old or older and who had suffered OHCA with sustained ROSC (defined as the presence of palpable pulses for > 20 min) and were comatose (Glasgow Coma Scale < 8) immediately after the arrest. Patients were excluded if they had blunt or penetrating injury as the primary cause of arrest, if they were pregnant, or if they were prisoners. The study was approved by the institutional review board at each participating site and the designated legally authorized surrogate provided written informed consent for each subject.
Data Collection and Data Management
Data were abstracted from the Emergency Medical Service reports, ED charts, and hospital records using standardized definitions (10) . We collected demographics and other baseline characteristics including initial cardiac arrest rhythm, initial vital signs, and laboratory results. We assessed the presence or absence of bystander cardiopulmonary resuscitation (CPR) and subject downtimes. We recorded pharmacologic interventions, including the use of vasoactive agents, sedatives or neuromuscular blocking agents, and antiepileptic medications. We recorded the results of diagnostic testing, including radiograph, echocardiogram, and CT results. Therapeutic hypothermia data and the results of cardiac catheterization procedures were recorded. Vital signs and laboratory data including lactate levels were collected at baseline (within 3 hr of sustained ROSC) and every 12 hours up to a maximum of 48 hours after the arrest.
Neurologic examinations were performed serially and at hospital discharge. Data were collected locally, removed of any personal identifying information, and entered into a secure electronic database that was shared across participating sites.
Outcome Measures
For the current analysis, the primary outcome measure was difference in percent lactate change at 12 hours between in-hospital survivors and nonsurvivors similar to previous investigation (9) . Secondary outcome measures included association of initial lactate with mortality, association of lactate change with good neurologic outcome, and differences in lactate between survivors and nonsurvivors at additional time points. We defined percent lactate change at X hour as follows: ([Lactate at 0 hr -lactate at X hr]/lactate at 0 hr) × 100%. We used the modified Rankin scale to assess neurologic outcome as recommended per recent AHA outcome guidelines (11, 12) . This is a validated scale, ranging from 0 to 6, that is used for measuring the performance of daily activities by patients who have suffered a stroke and is used commonly in cardiac arrest investigations (13, 14) . Lower scores represent better performance; scores of 4 or greater represent severe disability or death. Good neurologic outcome was defined as a modified Rankin scale of 0-3 and bad neurologic outcome as a modified Rankin scale of 4-6. In addition to the primary analyses, we tested the difference in median lactate values between survivors and nonsurvivors at the 0-, 12-, and 24-hour time points. For the purpose of this analysis, downtime is defined as the time of recognition of cardiac arrest to the time of ROSC.
Statistical Analysis
Simple descriptive statistics were used to summarize the study population. Data for continuous variables are presented as means with sds or median with interquartile ranges depending on normality of the data. Categorical data are presented as frequencies with percentages. Lactate levels between groups were compared using Wilcoxon signed rank test. We used Bonferroni method to account for multiple comparisons. In order to normalize the data, lactate values were log transformed prior to calculating the lactate change variable. A logistic regression was performed to determine the ability of lactate change at 12 hours to predict in-hospital mortality and favorable neurologic outcome. All explanatory variables were tested and those which were significant (p < 0.05) were then included in multiple logistic regression models for the purpose of assessing the significance of percent lactate change at 12 hours. Initial lactate was forced into the model. The percent lactate change was also examined at the 24-hour time point. In order to account for missing data, we conducted a sensitivity analysis with multiple imputations for the primary outcome of lactate change at 12 hours. The results from this analysis were not different from the primary analysis.
To analyze the ability of lactate levels to predict mortality and neurologic outcome at different time points, we created the receiver operating characteristic (ROC) curve and calculated the area under the curve (AUC).
Patients were divided into six groups based on initial lactate levels (< 5, 5-10, and > 10 mmol/L) and initial vasopressor support versus no vasopressor support within 1 hour after ROSC for a subgroup analysis using lactate in a model to predict survival. All tests of the data were performed in SAS v. 9.3 (SAS Institute, Cary, NC).
RESULTS
A total of 111 OHCA patients were enrolled ( Fig. 1) . One hundred patients had initial lactate levels measured and were included in the analysis. Baseline characteristics for these patients are shown in Table 1 . Overall survival was 46% and overall good neurologic outcome was 30%. Of those who survived to discharge, 65% had a good neurologic outcome. Ninety-seven percent of patients received therapeutic hypothermia. Baseline characteristics for the overall population and for survivors and nonsurvivors are shown in Table 1 .
Survivors had lower median lactate levels at 0, 12, and 24 hours compared with nonsurvivors (Table 2 and Fig. 2) . Patients with good neurologic outcome had lower median lactate levels at 0, 12, and 24 hours compared with patients with poor neurologic outcome ( Table 2 ). For the endpoint of percent lactate change at 12 hours, the unadjusted model revealed a change of 44% (10-67) versus 32% (-24 to 54) (p = 0.21) for survivors and nonsurvivors, respectively. After step-wise adjustment for variables found to be independent predictors of mortality (including initial lactate levels), percent reduction in lactate at 12 hours was statistically significantly associated with higher mortality (odds ratio [OR], 2.2; 95% CI, 1.1-6.2; p = 0.02) ( Fig. 3) . Between patients with good and bad neurologic outcome, unadjusted models showed a percent lactate change of 44% (15-67) versus 32% (-21 to 56) (p = 0.25), respectively. In the adjusted model, we found that less percent lactate change at 12 hours was statistically significantly associated with higher rate of bad neurologic outcome (OR, 2.2; 95% CI, 1.1-4.4; p = 0.02) ( Fig. 4) . There was a difference in percent lactate change between survivors and nonsurvivors at 24 hours (62% vs 36% [-9 to 59]; p = 0.03). There was a trend toward larger percent lactate change at 24 hours in those with good neurologic outcome, but this did not reach statistical significance (62% vs 37% [-9 to 63]; p = 0.08).
We analyzed the ability of lactate to predict mortality and neurologic outcome at different time points by creating the ROC curve (not shown) and calculating the AUC. The AUC for predicting mortality was 0.67 (0 hr), 0.76 (12 hr), and 0.78 (24 hr). The AUC for predicting bad neurologic outcome was 0.67 (0 hr), 0.72 (12 hr), and 0.77 (24 hr).
Patients were divided into six groups based on initial lactate levels (< 5, 5-10, and > 10 mmol/L) and initial vasopressor support versus no vasopressor support within 1 hour after ROSC. Figure 5 illustrates mortality that was significantly different between the groups (p = 0.002).
The amount of intra-arrest epinephrine (mg) was correlated with the initial lactate level (r = 0.22, p = 0.03); however, this relationship was no longer present after adjusting for downtime (r = 0.19, p = 0.08).
DISCUSSION
We found that greater percent lactate change over the first 12 hours post arrest was associated with lower mortality and better neurologic outcome in a cohort of OHCA patients. These differences held up after adjusting for potential confounders indicating that early lactate reduction is an independent predictor of mortality in postarrest patients. In addition, the initial lactate level was higher in nonsurvivors and those who had poor neurologic outcome as compared with survivors and those with good neurologic outcome. Survivors had lower lactate measurements at all time points (0, 12, and 24 hr) (Fig. 2) . Our findings are consistent with those previously reported in retrospective single-center studies of postarrest patients and consistent with findings from other disease states. Effective lactate clearance and lower initial lactate have been associated with reduced mortality in a variety of critical ill patients, including patients with trauma, burns, and sepsis (15) (16) (17) . In post-cardiac arrest patients, previous investigators have demonstrated an association between lactate clearance and in-hospital mortality. Kliegel All lactate levels are expressed as median (interquartile range). Figure 3 . Lactate levels and mortality in patients administered vasopressors versus patients not administered vasopressors. p = 0.002 for comparison between groups. et al (7) retrospectively studied cardiac arrest patients with survival beyond 48 hours and found that lactate levels at 48 hours were an independent predictor of mortality. Furthermore, they showed that survivors had lower initial lactate levels (7) which was confirmed by the current study. In a retrospective study of 79 patients, Donnino et al (8) found that lactate clearance at 12 hours was associated with 24-hour survival. However, initial lactate was not different between survivors and nonsurvivors. The initial lactate levels reported by Donnino et al (8) were substantially higher than the current average from our multicenter study likely reflecting an overall sicker population in that study. Patients reported by Donnino et al (8) had longer downtimes, were less likely to receive bystander CPR, and had overall higher mortality levels. Thus, the lack of a statistically different initial lactate level may reflect a clustering of patients with severe postarrest syndrome and not an inability of initial lactate to differentiate outcomes for the broader population. The combination of initial lactate and the need for vasopressor support have been showed to accurately predict mortality in one retrospective study of postcardiac arrest patients (18) . We conducted the same analysis and found similar results. All groups except the group with lactate 5-10 mmol/L and no vasopressor had similar mortality in the two studies showing that the simple combination of initial lactate and the use of vasopressors immediately post arrest accurately predicts mortality.
The pathophysiology of elevated lactate in post-cardiac arrest is complex and likely multifactorial. Prearrest, intra-arrest, and postarrest factors influence lactate levels and potentially lactate clearance. The initially elevated lactate likely reflects the ischemia-reperfusion injury combined with any tissue hypoperfusion that may be present from the underlying etiology of arrest. For example, a pulmonary embolism may cause underlying lactic acidosis prior to arrest from tissue hypoperfusion that is then markedly accentuated after the ischemia-reperfusion insult of the arrest. The persistent elevation of lactate or the effective change in lactate likely depends on the factors governing the initial elevation in conjunction with postarrest conditions. In the postarrest period, tissue hypoperfusion may persist for multiple reasons, including the lack of resolution of the underlying insult, a postarrest systemic inflammatory response (19, 20) , myocardial depression with resultant cardiogenic shock (21) , microcirculatory dysfunction (22) (23) (24) , and mitochondrial injury (25, 26) . The development of other complications such as sepsis (27) , bowel ischemia (28, 29) , seizures (30) , and/or adrenal insufficiency causing shock (31) could play a role if present. Another potential cause of elevated lactate levels in the postarrest period may be the presence of a hyper metabolic state with accelerated aerobic glycolysis potentially caused by activation of the Na+ K+ ATPase by endogenous epinephrine (32, 33) . The use of epinephrine has been suggested to cause elevated lactate (34) , but an earlier study did not find a correlation between intra-arrest epinephrine and early lactate clearance (9) . The current study found a weak correlation between the amount of intra-arrest epinephrine and initial lactate, but the difference was not significant when adjusting for downtime. Whether lactate clearance is affected by the use of induced hypothermia could not be examined in this current study since almost all patients (97%) received induced hypothermia.
The ideal endpoints of resuscitation in postarrest remain controversial (6) . Although our data (and that of others) show that lactate is associated with worse outcome, utilization of lactate as an endpoint of resuscitation remains unproven though physiologically plausible. If elevated lactate postarrest mostly represents injury from the initial ischemia-reperfusion injury to cells or from irreversible damage, the value of lactate would seemingly be less useful as a barometer for success of postarrest treatments. In contrast, if persistence of lactate represents ongoing correctable tissue hypoxia, one could conceivably adjust care based on lactate levels. Given that change in lactate at 12 hours is an independent predictor of survival after adjustment for arrest characteristics, our data suggest that at least some component of lactate change is dependent on the postarrest course and therefore potentially useful as an endpoint of resuscitation. Future research could be targeted at adjunctive therapies to improve lactate clearance, and investigators might consider lactate change as an intermediary endpoint in postarrest trials. In addition, lactate change could be evaluated as part of a severity of illness model in future prospective studies.
The current study has some limitations. The measurement of lactate levels was not part of the overall protocol, and lactate levels were only ordered if deemed appropriate by the treating physician. That said, 90% (100 of 111) had an initial lactate drawn. Table 2 illustrates the number of lactate levels at each time point within those who had lactate drawn initially, and our primary endpoint of lactate change between 0 and 12 hours had 85 of 100 of lactate measurements available (85%). Thus, some selection bias may have occurred, but we believe this was minimized by the strong majority of patients with this measurement available. We furthermore conducted a sensitivity analysis using a multiple imputations method for our primary analysis that did not alter our main results. The lactate samples were not all drawn from either arterial or venous sites; however, studies have shown that there is a high correlation between arterial and venous lactate levels (35) . Lactate analyzers were not standardized across the centers. However, differences in centers were evaluated in the multivariable model. Finally, although the study was multicenter, the sample size was relatively small.
CONCLUSION
Lower lactate levels at 0, 12, and 24 hours and greater percentage lactate reduction at 12 hours are associated with improved survival and good neurologic outcome in post-cardiac arrest patients. The use of percent lactate change as an endpoint of resuscitation warrants further research.
